Physician profile
David A Gunzel
NPI 1114948544
$524.84
in general payments reported to CMS, 2019-2025
11 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.18 · 2021: $11.74 · 2022: $30.55 · 2023: $215 · 2024: $113 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $328.15 | 2023-2025 | Puraply, Affinity, Cygnus Dual |
| Kerecis Limited | $36.53 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Trice Medical, INC. | $33.04 | 2024 | |
| Solventum Corporation | $25.87 | 2024 | Silvercel, 3m Coban, Promogran Prisma |
| Smith+Nephew, INC. | $17.82 | 2022 | |
| Abbvie INC. | $15.99 | 2024 | |
| Reprise Biomedical, INC. | $14.56 | 2025 | Miro3d |
| Vertex Pharmaceuticals Incorporated | $14.23 | 2025 | |
| Amgen INC. | $14.18 | 2020 | |
| Hartmann USA, INC. | $12.73 | 2022 | |
| Genentech USA, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gunzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.